The findings unveil that G-CSF is ineffective in improving patient survival and other clinical endpoints including MELD score, CLIF-C organ failure score, and the occurrence of infection, recommending G-SCF not be used as a standard treatment for ACLF (168). This evidence concerns the gene CSF3 and infection.